MAFENIDE


Synonyms	4-homosulfanilamide D06BA03 Mafenide NSC-34632 Sulfamylon
Status
Molecule Category	Free-form
ATC	D06BA03
UNII	58447S8P4L
EPA CompTox	DTXSID6047860

Structure


InChI Key	TYMRLRRVMHJFTF-UHFFFAOYSA-N
Smiles	NCc1ccc(S(N)(=O)=O)cc1
InChI	InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C7H10N2O2S
Molecular Weight	186.24
AlogP	-0.21
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	2.0
Polar Surface Area	86.18
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	12.0

Pharmacology

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Lyase	-	-	-	0.3-973	-
Enzyme	-	-	-	0.3-973	-

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Astrosclera willeyana	-	-	-	973	-
Brucella suis	-	-	-	768	-
Candida glabrata	-	-	-	865	-
Colwellia psychrerythraea	-	-	-	562	-
Enterobacter sp.	-	-	-	93.6	-
Helicobacter pylori	-	-	-	170-873	-
Homo sapiens	-	-	-	0.3-612	-
Legionella pneumophila subsp. pneumophila str. Philadelphia 1	-	-	-	516-757	-
Leishmania donovani chagasi	-	-	-	350	-
Malassezia globosa CBS 7966	-	-	-	174	-
Methanosarcina thermophila	-	-	-	350-350	-
Mus musculus	-	-	-	41-970	-
Nostoc commune	-	-	-	825-825	-
Plasmodium falciparum	-	-	-	904	-
Porphyromonas gingivalis	-	-	-	783-945	-
Saccharomyces cerevisiae	-	-	-	433	-
Stylophora pistillata	-	-	-	82.5-508	-
Sulfurihydrogenibium yellowstonense	-	-	-	350-350	-
Thalassiosira weissflogii	-	-	-	424	-
Thiomicrospira crunogena XCL-2	-	-	-	202	-
Vibrio cholerae	-	-	-	80.6-447	-

Related Entries

Cross References

Resources	Reference
ChEBI	6633
ChEMBL	CHEMBL419
DrugBank	DB06795
DrugCentral	1624
FDA SRS	58447S8P4L
KEGG	C07106
PDB	6LH
PubChem	3998
SureChEMBL	SCHEMBL41628
ZINC	ZINC000000001644

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).